IMPACT web portal: oncology database integrating molecular profiles with actionable therapeutics.

IMPACT web portal: oncology database integrating molecular profiles with actionable therapeutics.

Publication date: Apr 20, 2018

With the advancement of next generation sequencing technology, researchers are now able to identify important variants and structural changes in DNA and RNA in cancer patient samples. With this information, we can now correlate specific variants and/or structural changes with actionable therapeutics known to inhibit these variants. We introduce the creation of the IMPACT Web Portal, a new online resource that connects molecular profiles of tumors to approved drugs, investigational therapeutics and pharmacogenetics associated drugs.

IMPACT Web Portal contains a total of 776 drugs connected to 1326 target genes and 435 target variants, fusion, and copy number alterations. The online IMPACT Web Portal allows users to search for various genetic alterations and connects them to three levels of actionable therapeutics. The results are categorized into 3 levels: Level 1 contains approved drugs separated into two groups; Level 1A contains approved drugs with variant specific information while Level 1B contains approved drugs with gene level information. Level 2 contains drugs currently in oncology clinical trials. Level 3 provides pharmacogenetic associations between approved drugs and genes.

IMPACT Web Portal allows for sequencing data to be linked to actionable therapeutics for translational and drug repurposing research. The IMPACT Web Portal online resource allows users to query genes and variants to approved and investigational drugs. We envision that this resource will be a valuable database for personalized medicine and drug repurposing. IMPACT Web Portal is freely available for non-commercial use at http://tanlab.ucdenver.edu/IMPACT .

Open Access PDF

Hintzsche, J.D., Yoo, M., Kim, J., Amato, C.M., Robinson, W.A., and Tan, A.C. IMPACT web portal: oncology database integrating molecular profiles with actionable therapeutics. 05535. 2018 BMC Med Genomics (11):Suppl 2.

Concepts Keywords
BMC Drug repositioning
Clinical Trials DNA sequencing
Genetic Clinical trial
Pharmacogenetics Targeted therapy
Sequencing Pharmacy
Pharmacogenomics
Pharmacology
Genomics
Pharmaceutical industry
Drug discovery
Branches of biology
Health
Molecular profiles tumors
Therapy Neoplasms
Search genetic alterations
Pharmacogenetics
Http

Semantics

Type Source Name
gene UNIPROT PTPN5
gene UNIPROT CLOCK
gene UNIPROT SCN8A
gene UNIPROT TNFSF13
gene UNIPROT ANP32B
gene UNIPROT COL25A1
gene UNIPROT LAT2
drug DRUGBANK Palbociclib
gene UNIPROT DELE1
gene UNIPROT CDKN2A
drug DRUGBANK Dabrafenib
gene UNIPROT NRAS
gene UNIPROT MENT
drug DRUGBANK Trestolone
drug DRUGBANK Vemurafenib
drug DRUGBANK Trametinib
disease DOID fenib
pathway BSID Melanoma
disease DOID melanoma
disease MESH melanoma
drug DRUGBANK Coenzyme M
gene UNIPROT BRAF
gene UNIPROT SGSM3
gene UNIPROT BPIFA4P
gene UNIPROT DEPP1
gene UNIPROT GOPC
gene UNIPROT IGFALS
disease DOID als
gene UNIPROT ELAVL2
drug DRUGBANK Huperzine B
gene UNIPROT RBBP6
gene UNIPROT PRKRA
gene UNIPROT TNFRSF11A
drug DRUGBANK Pentaerythritol tetranitrate
gene UNIPROT AURKA
gene UNIPROT HAVCR1
disease MESH separated
disease DOID cancer
disease MESH cancer
gene UNIPROT IMPACT

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *